• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hope rises out of despair: bedaquiline and linezolid for the treatment of drug-resistant TB.

作者信息

Furin J, Akkerman O W

机构信息

Harvard Medical School, Department of Global Health and Social Medicine, Boston, MA, USA.

Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, Tuberculosis Center Beatrixoord, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, <email></email>, Email:

出版信息

Int J Tuberc Lung Dis. 2020 Oct 1;24(10):987-988. doi: 10.5588/ijtld.20.0379.

DOI:10.5588/ijtld.20.0379
PMID:33126928
Abstract
摘要

相似文献

1
Hope rises out of despair: bedaquiline and linezolid for the treatment of drug-resistant TB.希望从绝望中升起：贝达喹啉与利奈唑胺用于治疗耐药结核病。
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):987-988. doi: 10.5588/ijtld.20.0379.
2
Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen.氟喹诺酮类耐药结核病患者在接受贝达喹啉为基础的治疗方案时，中断利奈唑胺。
Int J Infect Dis. 2019 Aug;85:74-79. doi: 10.1016/j.ijid.2019.04.028. Epub 2019 May 14.
3
Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman.贝达喹啉和利奈唑胺治疗妊娠期广泛耐药结核病。
Emerg Infect Dis. 2017 Oct;23(10):1731-2. doi: 10.3201/eid2310.161398. Epub 2017 Oct 17.
4
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.在德国，将新型或第5组干预措施添加到背景治疗方案中用于治疗耐多药结核病的成本效益。
BMC Health Serv Res. 2017 Mar 8;17(1):182. doi: 10.1186/s12913-017-2118-2.
5
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.含贝达喹啉方案治疗耐多药和广泛耐药结核病的疗效和安全性：一项多中心研究。
Eur Respir J. 2017 May 21;49(5). doi: 10.1183/13993003.00387-2017. Print 2017 May.
6
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.新型耐药结核病 6 个月疗程，美国。
Emerg Infect Dis. 2021 Jan;27(1):332-4. doi: 10.3201/eid2701.203766. Epub 2020 Nov 23.
7
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.广泛耐药结核病的循证定义。
Am J Respir Crit Care Med. 2021 Sep 15;204(6):713-722. doi: 10.1164/rccm.202009-3527OC.
8
Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.南非广泛耐药结核病患者长期使用贝达喹啉相关治疗结局。
Eur Respir J. 2018 May 30;51(5). doi: 10.1183/13993003.00544-2018. Print 2018 May.
9
First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.乌干达首例广泛耐药结核分枝杆菌临床分离株全基因组分析报告，该分离株对贝达喹啉、利奈唑胺和氯法齐明耐药。
Antimicrob Resist Infect Control. 2022 May 12;11(1):68. doi: 10.1186/s13756-022-01101-2.
10
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.贝达喹啉治疗南非利福平耐药结核病的增量成本效果：基于模型的分析。
Appl Health Econ Health Policy. 2018 Feb;16(1):43-54. doi: 10.1007/s40258-017-0352-8.

引用本文的文献

1
Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.高人类免疫缺陷病毒（HIV）负担的南非农村地区，使用贝达喹啉为基础的全口服较短疗程方案治疗耐利福平结核病的安全性和有效性：一项回顾性队列分析。
Clin Infect Dis. 2021 Nov 2;73(9):e3563-e3571. doi: 10.1093/cid/ciaa1894.